Skip to main
MEDP
MEDP logo

Medpace Holdings (MEDP) Stock Forecast & Price Target

Medpace Holdings (MEDP) Analyst Ratings

Based on 11 analyst ratings
Hold
Strong Buy 0%
Buy 9%
Hold 64%
Sell 9%
Strong Sell 18%

Bulls say

Medpace Holdings is forecasting an increase in passthrough revenues by 200-300 basis points in the second half of the year compared to the elevated levels in the second quarter, indicating strong business momentum. The company experienced a robust first quarter, leading to higher Request for Proposal (RFP) volumes and contributing to positive growth indicators. Additionally, Medpace anticipates a return to a book-to-bill ratio exceeding 1.15x in the third quarter, reflecting strong demand for its services and a healthy revenue outlook.

Bears say

The analysis of Medpace Holdings indicates a concerning trend regarding its backlog cancellations, which have fluctuated significantly and were at the higher end of normal levels for the quarter. While the company anticipates no significant decline in Direct Service revenue for 2026, there remains a significant degree of uncertainty regarding its growth potential. Furthermore, the adjusted EBITDA estimates for 2025 and 2026 reflect an increase but are influenced by ongoing hiring costs, alongside a projected decrease in passthrough revenues, contributing to a negative outlook on the company's financial performance.

Medpace Holdings (MEDP) has been analyzed by 11 analysts, with a consensus rating of Hold. 0% of analysts recommend a Strong Buy, 9% recommend Buy, 64% suggest Holding, 9% advise Selling, and 18% predict a Strong Sell.

This aggregate rating is based on analysts' research of Medpace Holdings and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Medpace Holdings (MEDP) Forecast

Analysts have given Medpace Holdings (MEDP) a Hold based on their latest research and market trends.

According to 11 analysts, Medpace Holdings (MEDP) has a Hold consensus rating as of Dec 15, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $465.18, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $465.18, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Medpace Holdings (MEDP)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.